Abstract

Hook microtubule-tethering protein 3 (HOOK3) is an adaptor protein for microtubule-dependent intracellular vesicle and protein trafficking. In order to assess the role of HOOK3 in prostate cancer we analyzed HOOK3 expression by immunohistochemistry on a TMA containing more than 12,400 prostate cancers. Results were compared to tumor phenotype and PSA recurrence as well as aberrations possibly defining relevant molecular subtypes such as ERG status and deletions of 3p13, 5q21, 6q15 and PTEN. HOOK3 immunostaining was negative in normal luminal cells of prostate epithelium, whereas 53.3% of 10,572 interpretable cancers showed HOOK3 expression, which was considered low in 36.4% and high in 16.9% of cases. High-level HOOK3 expression was linked to advanced tumor stage, high Gleason score, high proliferation index, positive lymph node stage, and PSA recurrence (p<0.0001 each). The prognostic role of HOOK3 expression was independent of established clinico-pathological parameters both in preoperative and postoperative settings. Comparisons with molecular features were performed to draw conclusions on the potential function of HOOK3 in the prostate. A strong association with all examined deletions is consistent with a role of HOOK3 for maintaining genomic integrity by contributing to proper centrosome assembly. Finding HOOK3 expression in 74% of ERG positive but in only 38% of ERG negative cancers (p<0.0001) further suggests functional interactions between these genes. In conclusion, the results of our study identify HOOK3 as a strong candidate prognostic marker with a possible role in maintaining genomic integrity in prostate cancer, which may have potential for inclusion into clinical routine assays.

Highlights

  • Prostate cancer is the most prevalent cancer in men in Western societies [1]

  • The results of this study demonstrate that high-level Hook microtubule-tethering protein 3 (HOOK3) expression is an independent predictor of early prostate-specific antigen (PSA) recurrence in prostate cancer

  • Our immunohistochemical analysis revealed cytoplasmic HOOK3 staining in 85.0% of 10,572 analyzable prostate cancers

Read more

Summary

Introduction

While most tumors have a rather indolent clinical course, prostate cancer still represents the third most common cause of cancer related death in men. Established prognostic parameters are Gleason grade, tumor extent on biopsies, preoperative prostate-specific antigen (PSA), and clinical stage. Statistically powerful, they are not sufficient for optimal individual treatment decisions. A cancer relevant role has been suggested for HOOK3 from several studies finding recurrent alterations of the gene. HOOK3 gene is located at 8p11, a common breakpoint in many human tumor types, including prostate cancer [10,11]. Inactivating breakage resulting in reduced expression of HOOK3 was found in a considerable fraction (9.0%) of tumors [11] in a study on 77 prostate cancers

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call